Compare Enveric Biosciences Inc (ENVB) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs ProShares UltraPro QQQ ETF — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while ProShares UltraPro QQQ ETF trades at $81.11 (market cap $38.74B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 5697.1× Enveric Biosciences Inc's market cap, and ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| ENVB | TQQQ | |
|---|---|---|
Market Cap | $6.80M | $38.74B |
Volume | 64,867 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $10.80 | $87.22 |
52-Week Low | $1.27 | $37.89 |
Typical Hold Time | 14 Days | 24 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
TQQQ trades at $80.67, down 3.5% in the last session amid mixed technical signals. The ETF maintains a bullish overall technical rating with strong moving average support but faces neutral oscillators. Recent news highlights significant hidden costs beyond the stated 0.82% expense ratio, including financing charges that impact returns. Institutional activity shows mixed positioning with some firms reducing stakes while others add exposure.
Outlook remains volatile given TQQQ's 3x leveraged structure, which amplifies both gains and losses. The ETF faces headwinds from volatility decay and hidden costs, though AI-driven tech growth provides underlying support. Key risks include amplified drawdowns during market corrections and structural costs that erode long-term performance versus the underlying index.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
